KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Payables (2016 - 2025)

Novavax (NVAX) has 16 years of Payables data on record, last reported at $24.6 million in Q4 2025.

  • For Q4 2025, Payables fell 40.89% year-over-year to $24.6 million; the TTM value through Dec 2025 reached $24.6 million, down 40.89%, while the annual FY2025 figure was $24.6 million, 40.89% down from the prior year.
  • Payables reached $24.6 million in Q4 2025 per NVAX's latest filing, up from $15.2 million in the prior quarter.
  • Across five years, Payables topped out at $710.7 million in Q2 2022 and bottomed at $15.2 million in Q3 2025.
  • Average Payables over 5 years is $168.1 million, with a median of $83.6 million recorded in 2023.
  • Peak YoY movement for Payables: surged 4411.72% in 2021, then crashed 87.72% in 2023.
  • A 5-year view of Payables shows it stood at $127.0 million in 2021, then surged by 326.13% to $541.4 million in 2022, then plummeted by 75.51% to $132.6 million in 2023, then plummeted by 68.65% to $41.6 million in 2024, then plummeted by 40.89% to $24.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $24.6 million in Q4 2025, $15.2 million in Q3 2025, and $50.6 million in Q2 2025.